DUSA (DUSA) Pharmaceutical Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : DUSA (DUSA) Pharmaceutical

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: bdusa1 who wrote (35)	7/27/1998 7:40:00 AM
From: ouija	Read Replies (2) of 101

Share price has gotten absurdly cheap for a company with its first NDA filed (for AK), not out of money, great efficacy, and many applications including very large ones yet to be filed in the not to distant future (bladder cancer diagnosis next). Discounting future revenues and earnings after approval for AK alone back by 30% per year put this stock into the 20s sometime next year. Typical reaction is 'What's wrong with this picture?'. Nothing that I've found, other than managements expectations screw up documented earlier.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next